A Phase 1 interventional study of Ipilimumab and Carboplatin in Advanced Melanoma, sponsored by Bristol-Myers Squibb. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-01-06.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 155 studies testing ipilimumab in Melanoma — 21 open to participants now, 42 under way, 5 of them phase 3. Ipilimumab · Melanoma.
Among the 155 studies testing ipilimumab in Melanoma, this one is the 50th largest by enrollment of the 152 interventional ones that give a count, is one of 6 that started in 2009, is one of 33 in phase 1, and was the 21st registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →21 of the 155 studies testing ipilimumab in Melanoma are open now, in 9 countries. Recruiting first, the newest first:
Swiss Cancer Institute · Sites in Switzerland
Ages 18+
Melanoma and Skin Cancer Trials Limited · Sites in Australia
Ages 18+
Radboud University Medical Center · Sites in Netherlands
Ages 18+
UNC Lineberger Comprehensive Cancer Center · Sites in United States
Ages 18+
NYU Langone Health · Sites in United States
Ages 18+
By country, each count listing its studies:
Ipilimumab: first FDA approval 2011 (YERVOY), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, ipilimumab is the treatment under test here. Read study by study →
155 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 103 · Phase 3 14 · Phase 4 2
First in 2001; this study’s year is marked. 6 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is above the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 30 across the 152 interventional studies. Of the 102 that completed or were terminated, 56 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 155 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
111 studies in Melanoma by Bristol-Myers Squibb: 3 open now, 9 under way, 3 of them phase 3. Of 90 finished, 41 (46%) have results posted.
Among the 111 studies in Melanoma by Bristol-Myers Squibb, this one is the 48th largest by enrollment of the 75 interventional ones that give a count, is one of 4 that started in 2009, is one of 21 in phase 1, and was the 24th registered.
Bristol-Myers Squibb’s Melanoma studies by the year they started, since 2002.
8 of the studies testing ipilimumab in Melanoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06712927Stanford UniversityTrial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases | 2026-11 |
| NCT07155317Emory UniversityTime-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial | 2026-12-31 |
| NCT05289193Memorial Sloan Kettering Cancer CenterCD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma | 2027-03-11 |
| NCT07422779Institute of Oncology LjubljanaImmunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia | 2027-03-31 |
| NCT03122522Memorial Sloan Kettering Cancer CenterA Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy | 2027-04 |
Add all 8 to your calendar (.ics) → With an account.
Among the 155 studies testing ipilimumab in Melanoma, from their registry updates:
Among Bristol-Myers Squibb’s 111 in Melanoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical research study is to learn the pharmacokinetics of Ipilimumab when combined with Paclitaxel/Carboplatin or Dacarbazine
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ipilimumab · Drug: Carboplatin · Drug: Paclitaxel
Drug: Ipilimumab · Drug: Dacarbazine
Drug: Ipilimumab
Solution, intravenous, 10mg/kg, every 3 weeks in the induction phase, up to 4 doses in the induction phase, 48 weeks
Also known as: BMS-734016, MDX-010
Solution, intravenous, Area Under the Concentration Time Curve=6, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
Also known as: BMY-26575, PARAPLATIN
Solution, intravenous, 175 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
Also known as: TAXOL, BMS-181339
Solution, intravenous, 850 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
Pharmacokinetic Parameter Maximum Observed Serum Concentration (Cmax) for Ipilimumab, Paclitaxel, Dacarbazine and the Active Metabolite for Dacarbazine, 5-aminoimidazole-4carboxamide (AIC)- Pharmacokinetic Analysis Population
Cmax=micrograms per milliliter (µg/mL): drug concentration versus time for ipilimumab (Day 43) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma by Enzyme-linked Immunosorbent Assay (ELISA); lower level of quantitation (LLOQ)=0.8 µg/mL; upper limit of quantitation (ULOQ)=25.6 µg/mL; Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; from Day 162 on every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined using liquid chromatography tandem mass spectrometry (LC/MS/MS) detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography atmospheric pressure ionization (API) tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose.
Time frame: Day 1 (0 h) to Day 43
Area Under the Concentration Time Curve (AUC) From Time Zero to 21 Days [AUC(0-21d)] for Ipilimumab and AUC Time Zero Extrapolated to Infinity [AUC(INF)] for Paclitaxel, Dacarbazine and the Active Metabolite AIC - Pharmacokinetic Analysis Population
AUC=micrograms\*hour(h) per mL (µg\*h/mL): derived from drug concentration versus time for ipilimumab (Day 43 only) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma ELISA; LLOQ=0.8 µg/mL; ULOQ=25.6 µg/mL; sample times on Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; starting Day 162 every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined from plasma using LC/MS/MS detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; sample times Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography API tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; sample times Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose.
Time frame: Day 1 (0 h) to Day 43
Pharmacokinetic Parameter of Time of Maximum Observed Concentration (Tmax) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population
Tmax reported in hours (h): derived from drug concentration versus time for ipilimumab (Day 43 only) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma ELISA; LLOQ=0.8 µg/mL; ULOQ=25.6 µg/mL; sample times on Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; starting Day 162 every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined from plasma using LC/MS/MS detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; sample times Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography API tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; sample times Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose..
Time frame: Day 1 (0 h) to Day 43
Pharmacokinetic Parameter of Terminal Elimination Half Life (T-HALF) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population
T(HALF) reported in hours (h): derived from drug concentration versus time for ipilimumab (Day 43 only) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma ELISA; LLOQ=0.8 µg/mL; ULOQ=25.6 µg/mL; sample times on Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; starting Day 162 every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined from plasma using LC/MS/MS detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; sample times Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography API tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; sample times Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose.
Time frame: Day 1 (0 h) to Day 43
Pharmacokinetic Parameter of Clearance (CLT) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population
CLT reported in milliliters/hour (mL/h): derived from drug concentration versus time for ipilimumab (Day 43 only) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma ELISA; LLOQ=0.8 µg/mL; ULOQ=25.6 µg/mL; sample times on Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; starting Day 162 every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined from plasma using LC/MS/MS detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; sample times Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography API tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; sample times Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose..
Time frame: Day 1 (0 h) to Day 43
Pharmacokinetic Parameter Volume of Distribution at Steady State (Vss) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population
Vss reported in liters(L): derived from drug concentration versus time for ipilimumab (Day 43 only) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma ELISA; LLOQ=0.8 µg/mL; ULOQ=25.6 µg/mL; sample times on Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; starting Day 162 every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined from plasma using LC/MS/MS detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; sample times Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography API tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; sample times Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose.
Time frame: Day 1 (0 h) to Day 43
Number of Participants in Best Overall Response Categories Based on Modified World Health Organization (mWHO) Criteria - All Treated Participants
Assessments for antitumor activity by physical exam and routine anatomic imaging were at Week 12 and confirmatory imaging at Weeks 16, 20, and 24. Participants with resected index or new lesions were considered progressed in their disease. Complete Response (CR): Complete disappearance of all index lesions; Partial Response (PR): Decrease, relative to baseline, of 50% or greater in the sum of the products of the two largest perpendicular diameters of all index lesions, in the absence of Complete Response; Stable Disease (SD): Does not meet criteria for complete or partial response, in the absence of progressive disease. Participants with PR or CR that was not confirmed after at least 4 weeks are scored as SD unless they have new primary lesions; Progressive Disease: At least 25% increase in the sum of products of all index lesions and/or the appearance of any new lesion(s). Unknown=the participants overall response was not known.
Time frame: Day 1 to Week 48
Number of Participants in Best Overall Response Categories Based on Immune Related (ir) Response Criteria (RC) - All Treated Participants
Assessments: Weeks 12, 16, 20, and 24. Participants with resected index or new lesions considered progressed in their disease. The immune-related (ir) response criteria (irRC) represents further modifications of mWHO criteria reflecting clinical experience with ipilimumab in which objective and durable responses (as per mWHO) were observed in participants following progression and without intervening alternative anti-cancer therapy. Immune-related (ir)Complete Response (irCR): Complete disappearance of all index lesions; ir Partial Response (irPR): Decrease, relative to baseline, of 50% or greater in sum of products of the two largest perpendicular diameters of all index and all new measurable lesions, in the absence of irCR; ir Stable Disease (irSD): Does not meet criteria for irCR or irPR, in the absence of progressive disease (PD); ir PD: At least 25% increase in Tumor Burden compared to sum of product diameters (SPD) at nadir. ir Unknown=participants overall response not known.
Time frame: Day 1 to Week 48
Number of Participants With Objective Response to Treatment and Disease Control Using mWHO Criteria - All Randomized Participants
Number of participants with an objective response to treatment excluded participants with a best overall response (BOR) of Stable Disease (SD). Disease control is non-progression of disease while on treatment. A participant was considered to have achieved disease control if he/she had a BOR of CR, PR, or SD in the absence of resected index lesions or new lesions while the participant was considered to have an objective response to treatment in he/she had a BOR of CR or PR in the absence of resected index lesions or new lesions.
Time frame: Day 1 to Week 48
Number of Participants With Adverse Events, Serious Adverse Events, Deaths, and Discontinuation Due to Adverse Events From Day 1 to Week 48 - All Treated Population
Adverse events (AEs) and Serious AEs (SAEs) were graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse events version 3.0. Week 48 database lock was 27 July 2010.
Time frame: Day 1 to Week 48
Mean Absolute Lymphocyte Count (ALC) at Each Nominal Ipilimumab Induction Dose and at End of the Induction Period - Pharmacodynamic Population
Absolute lymphocyte counts were obtained from routine hematology panels from 28 days prior to the first treatment with any study medication through the end of the Induction-Dosing Period and were reported as number\*10\^3 cells per micro liter (x10\^3 c/µL).
Time frame: Day to Week 12
Mean Change From Baseline at Weeks 16 and 48 in Diastolic and Systolic Blood Pressure - All Treated Population
Blood pressure was obtained while the participant was sitting down and was measured in millimeters of mercury (mmHg). During the induction phase blood pressure was collected 30 minutes prior to dosing and every 30 minutes for the duration of the ipilimumab infusion. Orthostatic blood pressure was to be measured when clinically indicated (for example, participant was experiencing lightheadedness, dizziness, syncope). Blood pressures were recorded at Weeks 1, 4, 7, 10,13, 16, 19, and 22 during the Induction Phase, and at Weeks 24, 36, and 48 during the Maintenance Phase.
Time frame: Day 1 to Week 48
Mean Change From Baseline in Pulse Rate at Weeks 16 and 48 - All Treated Population
Pulse rate was obtained while the participant was sitting down and measured in beats per minute (bpm). During the induction phase pulse rate was collected 30 minutes prior to dosing and every 30 minutes for the duration of the ipilimumab infusion. Pulse rate was recorded at Weeks 1, 4, 7, 10, 13, 16, 19, and 22 during the Induction Phase, and at Weeks 24, 36, and 48 during the Maintenance Phase.
Time frame: Day 1 to Week 48
Mean Change From Baseline in Respiration Rate at Weeks 16 and 48 - All Treated Population
Respiration rate was obtained while the participant was sitting down and measured in breaths per minute (bpm). During the induction phase respiration rate was collected 30 minutes prior to dosing and every 30 minutes for the duration of the ipilimumab infusion. Respiration rate was recorded at Weeks 1, 4, 7, 10, 13, 16, 19, and 22 during the Induction Phase, and at Weeks 24, 36, and 48 during the Maintenance Phase.
Time frame: Day 1 to Week 48
Mean Baseline Change in Body Temperature at Weeks 16 and 48 - All Treated Population
Temperature was obtained while the participant was sitting down and was measured in degrees Fahrenheit (F). During the induction phase this vital sign was collected 30 minutes prior to dosing and every 30 minutes for the duration of the ipilimumab infusion. Temperature was recorded at Weeks 1, 4, 7, 10, 13, 16, 19, and 22 during the Induction Phase, and at Weeks 24, 36, and 48 during the Maintenance Phase.
Time frame: Day 1 to Week 48
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst Common Terminology Criteria (CTC) Grade for Hemoglobin - All Treated Population
Hemoglobin was measured in grams per deciliter (g/dL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 10.0 - less than (\<) lower limit of normal (LLN); GRADE (2): 8.0 - \< 10.0; GRADE (3): 6.5 - \< 8.0; GRADE (4): \< 6.5
Time frame: Day 1 to Week 48
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst Common Terminology Criteria (CTC) Grade for Leukocytes - All Treated Population
Leukocytes are measured as \*10\^3 cells per microliter (c/µL). National Cancer Institute Common Terminology Criteria (CTC) version (v) 3.0 was used to determine Grade. GRADE (1): 3.0 - \< LLN; GRADE (2): 2.0 - \< 3.0; GRADE (3): 1.0 - \< 2.0; GRADE (4): \< 1.0.
Time frame: Day 1 to Week 48
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst Common Terminology Criteria (CTC) Grade for Lymphocytes - All Treated Population
Lymphocytes (absolute) were measured as \*10\^3 cells per microliter (c/µL). National Cancer Institute Common Terminology Criteria (CTC) version (v) 3.0 was used to determine Grade. GRADE (1): 0.8 - \< 1.5; GRADE (2): 0.5 - \< 0.8; GRADE (3): 0.2 - \< 0.5; GRADE (4): \< 0.2
Time frame: Day 1 to Week 48
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Neutrophils - All Treated Population
Neutrophils (absolute) are measured as \*10\^3 cells per microliter (c/µL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 1.5 - \< 2.0; GRADE (2): 1.0 - \< 1.5; GRADE (3): 0.5 - \< 1.0; GRADE (4): \< 0.5
Time frame: Day 1 to Week 48
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Neutrophils Plus Bands - All Treated Population
Neutrophils plus bands (absolute) were measured as \*10\^3 cells per microliter (c/µL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 1.5 - \< 2.0; GRADE (2): 1.0 - \< 1.5; GRADE (3): 0.5 - \< 1.0; GRADE (4): \< 0.5.
Time frame: Day 1 to Week 48
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Platelet Count - All Treated Population
Platelets were measured as \*10\^9 cells per liter (c/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 75.0 - \< LLN; GRADE (2): 50.0 - \< 75.0; GRADE (3): 25.0 - \< 50.0; GRADE (4): \< 25.0.
Time frame: Day 1 to Week 48
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Alanine Aminotransferase (ALT) - All Treated Population
ALT was measured as Units per Liter (U/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 - 2.5 \* upper limits of normal (ULN); GRADE (2): \> 2.5 - 5.0 \* ULN; GRADE (3): \> 5.0 - 20.0 \* ULN; GRADE (4): \> 20.0 \* ULN.
Time frame: Day 1 to Week 48
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Aspartate Aminotransferase (AST) - All Treated Population
AST was measured as Units per Liter (U/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 - 2.5 \* upper limits of normal (ULN); GRADE (2): \> 2.5 - 5.0 \* ULN; GRADE (3): \> 5.0 - 20.0 \* ULN; GRADE (4): \> 20.0 \* ULN.
Time frame: Day 1 to Week 48
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Albumin - All Treated Population
Albumin was measured in grams per deciliter (g/dL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \< LLN - 3.0; GRADE (2): \< 3.0 - 2.0; GRADE (3): \< 2.0 g/dL.
Time frame: Day 1 to Week 48
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Alkaline Phosphatase - All Treated Population
Alkaline Phosphatase was measured as Units per Liter (U/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 - 2.5 \* upper limits of normal (ULN); GRADE (2): \> 2.5 - 5.0 \* ULN; GRADE (3): \> 5.0 - 20.0 \* ULN; GRADE (4): \> 20.0 \* ULN.
Time frame: Day 1 to Week 48
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Bilirubin - All Treated Population
Total Bilirubin was measured as milligrams per deciliter (mg/dL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 - 1.5 \* upper limits of normal (ULN); GRADE (2): \> 1.5 - 3.0 \* ULN; GRADE (3): \> 3.0 - 10.0 \* ULN; GRADE (4): \> 10.0 \* ULN.
Time frame: Day 1 to Week 48
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Serum Potassium (High) - All Treated Population
Serum potassium was measured as milliequivalents per liter (mEq/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 3.0 - \< LLN OR \> ULN - 5.5;; GRADE (2): \> 5.5 - 6.0; GRADE (3): 2.5 - \< 3.0 \> 6.0 - 7.0; GRADE (4): \< 2.5 mEq/L.
Time frame: Day 1 to Week 48
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Amylase - All Treated Population
Amylase was measured as units per liter (U/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 - 1.5 \* upper limits of normal (ULN); GRADE (2): \> 1.5 - 2.0 \* ULN; GRADE (3): \> 2.0 - 5.0 \* ULN; GRADE (4): \> 5.0 \* ULN.
Time frame: Day 1 to Week 48
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Calcium (High) - All Treated Population
Total Calcium was measured as milligrams per deciliter (mg/dL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 8.0 - \< LLN OR \> ULN - 11.5; GRADE (2): 7.0 - \< 8.0 \> 11.5 - 12.5; GRADE (3): 6.0 - \< 7.0 \> 12.5 - 13.5; GRADE (4): \< 6.0 \> 13.5 mg/dL.
Time frame: Day 1 to Week 48
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Lipase - All Treated Population
Total Lipase (as measured with a turbidimetric assay) was measured as units per liter (U/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 - 1.5 \* ULN; GRADE (2): \> 1.5 - 2.0 \* ULN; GRADE (3): \> 2.0 - 5.0 \* ULN; GRADE (4): \> 5.0 X ULN.
Time frame: Day 1 to Week 48
Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Uric Acid - All Treated Population
Uric acid was measured as milligrams per deciliter (mg/dL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 \* ULN - 10.0; GRADE (4): \> 10.0 mg/dL.
Time frame: Day 1 to Week 48
17 February 2009 study initiated; last patient, last visit (LPLV) 30 October 2012.
| Milestone | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| Started | 20 | 19 | 20 |
| Completed | 5 | 7 | 6 |
| Not completed | 15 | 12 | 14 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Withdrew: Death | 2 | 0 | 0 |
| Withdrew: Disease progression | 10 | 9 | 7 |
| Withdrew: Study drug toxicity | 3 | 3 | 5 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
Cmax=micrograms per milliliter (µg/mL): drug concentration versus time for ipilimumab (Day 43) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma by Enzyme-linked Immunosorbent Assay (ELISA); lower level of quantitation (LLOQ)=0.8 µg/mL; upper limit of quantitation (ULOQ)=25.6 µg/mL; Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; from Day 162 on every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined using liquid chromatography tandem mass spectrometry (LC/MS/MS) detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography atmospheric pressure ionization (API) tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose.
| µg/mL | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| Cmax of Ipilimumab N=14, 14, 12 | 234.54 ± 29 | 246.50 ± 35 | 251.05 ± 34 |
| Cmax of Paclitaxel (Day 1) N=20, 0, 0 | 3.35 ± 23 | NA ± NA | NA ± NA |
| Cmax of Paclitaxel (Day 43) N=14, 0, 0 | 3.19 ± 26 | NA ± NA | NA ± NA |
| Cmax of Dacarbazine (Day 1) N=0, 19, 0 | NA ± NA | 18.23 ± 37 | NA ± NA |
| Cmax of Dacarbazine (Day 43) N=0, 16, 0 | NA ± NA | 18.61 ± 30 | NA ± NA |
| Cmax of AIC (Day 1) N=0, 19, 0 | NA ± NA | 3.57 ± 36 | NA ± NA |
| Cmax of AIC (Day 43) N=0, 17, 0 | NA ± NA | 3.98 ± 40 | NA ± NA |
Tmax reported in hours (h): derived from drug concentration versus time for ipilimumab (Day 43 only) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma ELISA; LLOQ=0.8 µg/mL; ULOQ=25.6 µg/mL; sample times on Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; starting Day 162 every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined from plasma using LC/MS/MS detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; sample times Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography API tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; sample times Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose..
| h | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| Tmax of Ipilimumab N=14, 14, 12 | 1.51 (1.5 to 24.0) | 4.00 (1.5 to 24.6) | 1.56 (1.5 to 4.0) |
| Tmax of Paclitaxel (Day 1) N=20, 0, 0 | 3.00 (2.9 to 4.3) | NA (NA to NA) | NA (NA to NA) |
| Tmax of Paclitaxel (Day 43) N=14, 0, 0 | 3.00 (1.5 to 9.5) | NA (NA to NA) | NA (NA to NA) |
| Tmax of Dacarbazine (Day 1) N=0, 18, 0 | NA (NA to NA) | 1.00 (1.0 to 2.8) | NA (NA to NA) |
| Tmax of Dacarbazine (Day 43) N=0, 15, 0 | NA (NA to NA) | 1.00 (1.0 to 1.1) | NA (NA to NA) |
| Tmax of AIC (Day 1) N=0, 19 0 | NA (NA to NA) | 1.00 (1.0 to 2.8) | NA (NA to NA) |
| Tmax of AIC (Day 43) N=0, 16, 0 | NA (NA to NA) | 1.00 (1.0 to 2.5) | NA (NA to NA) |
T(HALF) reported in hours (h): derived from drug concentration versus time for ipilimumab (Day 43 only) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma ELISA; LLOQ=0.8 µg/mL; ULOQ=25.6 µg/mL; sample times on Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; starting Day 162 every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined from plasma using LC/MS/MS detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; sample times Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography API tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; sample times Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose.
| h | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| T(HALF) of Ipilimumab N=14, 14, 12 | 13.93 ± 7.54 | 13.39 ± 4.51 | 15.25 ± 4.64 |
| T(HALF) of Paclitaxel (Day 1) N=20, 0, 0 | 10.26 ± 1.57 | NA ± NA | NA ± NA |
| T(HALF) of Paclitaxel (Day 43) N=14, 0, 0 | 10.41 ± 2.73 | NA ± NA | NA ± NA |
| T(HALF) of Dacarbazine (Day 1) N=0, 19, 0 | NA ± NA | 2.11 ± 0.87 | NA ± NA |
| T(HALF) of Dacarbazine (Day 43) N=0, 16, 0 | NA ± NA | 2.07 ± 0.85 | NA ± NA |
| T(HALF) of AIC (Day 1) N=0, 18, 0 | NA ± NA | 2.24 ± 0.96 | NA ± NA |
| T(HALF) of AIC (Day 43) N=0, 16, 0 | NA ± NA | 2.21 ± 0.81 | NA ± NA |
CLT reported in milliliters/hour (mL/h): derived from drug concentration versus time for ipilimumab (Day 43 only) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma ELISA; LLOQ=0.8 µg/mL; ULOQ=25.6 µg/mL; sample times on Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; starting Day 162 every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined from plasma using LC/MS/MS detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; sample times Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography API tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; sample times Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose..
| mL/h | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| CLT of Ipilimumab N=14, 14, 12 | 11.63 ± 50 | 11.17 ± 34 | 10.23 ± 44 |
| CLT of Paclitaxel (Day 1) N=20, 0, 0 | 27.87 ± 28 | NA ± NA | NA ± NA |
| CLT of Paclitaxel (Day 43) N=14, 0, 0 | 25.44 ± 26 | NA ± NA | NA ± NA |
| CLT of Dacarbazine (Day 1) N=0, 19, 0 | NA ± NA | 34.33 ± 52 | NA ± NA |
| CLT of Dacarbazine (Day 43) N=0, 16, 0 | NA ± NA | 37.09 ± 49 | NA ± NA |
| CLT of AIC (Day 1) N=0, 19, 0 | NA ± NA | 91.67 ± 28 | NA ± NA |
| CLT of AIC (Day 43) N=0, 17, 0 | NA ± NA | 88.75 ± 37 | NA ± NA |
AUC=micrograms\*hour(h) per mL (µg\*h/mL): derived from drug concentration versus time for ipilimumab (Day 43 only) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma ELISA; LLOQ=0.8 µg/mL; ULOQ=25.6 µg/mL; sample times on Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; starting Day 162 every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined from plasma using LC/MS/MS detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; sample times Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography API tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; sample times Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose.
| µg*h/mL | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| AUC(0-21d) of Ipilimumab N=14, 14, 12 | 46925.36 ± 36 | 49569.06 ± 25 | 54039.79 ± 28 |
| AUC(INF) of Paclitaxel (Day 1) N=20, 0, 0 | 12.37 ± 24 | NA ± NA | NA ± NA |
| AUC(INF) of Paclitaxel (Day 43) N=14, 0, 0 | 13.41 ± 24 | NA ± NA | NA ± NA |
| AUC(INF) of Dacarbazine (Day 1) N=0, 19, 0 | NA ± NA | 47.36 ± 68 | NA ± NA |
| AUC(INF) of Dacarbazine (Day 43) N=0, 16, 0 | NA ± NA | 41.13 ± 55 | NA ± NA |
| AUC(INF) of AIC (Day 1) N=0, 18, 0 | NA ± NA | 17.68 ± 26 | NA ± NA |
| AUC(INF) of AIC (Day 43) N=0, 16, 0 | NA ± NA | 17.38 ± 36 | NA ± NA |
Vss reported in liters(L): derived from drug concentration versus time for ipilimumab (Day 43 only) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma ELISA; LLOQ=0.8 µg/mL; ULOQ=25.6 µg/mL; sample times on Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; starting Day 162 every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined from plasma using LC/MS/MS detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; sample times Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography API tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; sample times Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose.
| L | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| Vss of Ipilimumab N=14, 14, 12 | 5.10 ± 25 | 4.88 ± 21 | 5.05 ± 29 |
| Vss of Paclitaxel (Day 43) N=14, 0, 0 | 205.63 ± 31 | NA ± NA | NA ± NA |
| Vss of Dacarbazine (Day 43) N=0, 16, 0 | NA ± NA | 107.90 ± 31 | NA ± NA |
| Vss of AIC (Day 1) N=0, 17, 0 | NA ± NA | 342.64 ± 47 | NA ± NA |
Assessments for antitumor activity by physical exam and routine anatomic imaging were at Week 12 and confirmatory imaging at Weeks 16, 20, and 24. Participants with resected index or new lesions were considered progressed in their disease. Complete Response (CR): Complete disappearance of all index lesions; Partial Response (PR): Decrease, relative to baseline, of 50% or greater in the sum of the products of the two largest perpendicular diameters of all index lesions, in the absence of Complete Response; Stable Disease (SD): Does not meet criteria for complete or partial response, in the absence of progressive disease. Participants with PR or CR that was not confirmed after at least 4 weeks are scored as SD unless they have new primary lesions; Progressive Disease: At least 25% increase in the sum of products of all index lesions and/or the appearance of any new lesion(s). Unknown=the participants overall response was not known.
| participants | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| Complete Response | 1 | 1 | 0 |
| Partial Response | 1 | 4 | 5 |
| Stable Disease | 6 | 5 | 4 |
| Progressive Disease | 9 | 8 | 8 |
| Unknown | 3 | 1 | 3 |
Assessments: Weeks 12, 16, 20, and 24. Participants with resected index or new lesions considered progressed in their disease. The immune-related (ir) response criteria (irRC) represents further modifications of mWHO criteria reflecting clinical experience with ipilimumab in which objective and durable responses (as per mWHO) were observed in participants following progression and without intervening alternative anti-cancer therapy. Immune-related (ir)Complete Response (irCR): Complete disappearance of all index lesions; ir Partial Response (irPR): Decrease, relative to baseline, of 50% or greater in sum of products of the two largest perpendicular diameters of all index and all new measurable lesions, in the absence of irCR; ir Stable Disease (irSD): Does not meet criteria for irCR or irPR, in the absence of progressive disease (PD); ir PD: At least 25% increase in Tumor Burden compared to sum of product diameters (SPD) at nadir. ir Unknown=participants overall response not known.
| participants | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| ir Complete Response | 1 | 1 | 0 |
| ir Partial Response | 4 | 5 | 5 |
| ir Stable Disease | 5 | 5 | 6 |
| ir Progressive Disease | 7 | 7 | 6 |
| ir Unknown | 3 | 1 | 3 |
Number of participants with an objective response to treatment excluded participants with a best overall response (BOR) of Stable Disease (SD). Disease control is non-progression of disease while on treatment. A participant was considered to have achieved disease control if he/she had a BOR of CR, PR, or SD in the absence of resected index lesions or new lesions while the participant was considered to have an objective response to treatment in he/she had a BOR of CR or PR in the absence of resected index lesions or new lesions.
| participants | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| Participants with Objective Response | 2 | 5 | 5 |
| Participants with Disease Control | 8 | 10 | 9 |
Adverse events (AEs) and Serious AEs (SAEs) were graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse events version 3.0. Week 48 database lock was 27 July 2010.
| participants | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| Participants with AEs | 20 | 19 | 20 |
| Participants with SAEs | 9 | 8 | 9 |
| Participants with SAEs Treatment-Related | 4 | 6 | 5 |
| Deaths | 12 | 5 | 7 |
| Deaths Treatment-Related | 0 | 0 | 0 |
| Participants discontinued due to AE(s) | 6 | 7 | 5 |
Absolute lymphocyte counts were obtained from routine hematology panels from 28 days prior to the first treatment with any study medication through the end of the Induction-Dosing Period and were reported as number\*10\^3 cells per micro liter (x10\^3 c/µL).
| 10^3 cells/µL | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| Nominal Ipilimumab Induction Dose Number 1 | 1.19 (0.79 to 1.59) | 1.41 (1.00 to 1.82) | 1.28 (0.91 to 1.64) |
| Nominal Ipilimumab Induction Dose Number 2 | 1.62 (1.27 to 1.98) | 2.05 (1.69 to 2.42) | 1.56 (1.18 to 1.93) |
| Nominal Ipilimumab Induction Dose Number 3 | 1.43 (1.06 to 1.80) | 1.96 (1.59 to 2.33) | 1.99 (1.59 to 2.39) |
| Nominal Ipilimumab Induction Dose Number 4 | 1.42 (1.03 to 1.80) | 1.87 (1.49 to 2.25) | 1.80 (1.39 to 2.22) |
| End of Ipilimumab Induction dosing Period | 1.67 (1.23 to 2.10) | 2.07 (1.63 to 2.51) | 1.73 (1.20 to 2.25) |
Blood pressure was obtained while the participant was sitting down and was measured in millimeters of mercury (mmHg). During the induction phase blood pressure was collected 30 minutes prior to dosing and every 30 minutes for the duration of the ipilimumab infusion. Orthostatic blood pressure was to be measured when clinically indicated (for example, participant was experiencing lightheadedness, dizziness, syncope). Blood pressures were recorded at Weeks 1, 4, 7, 10,13, 16, 19, and 22 during the Induction Phase, and at Weeks 24, 36, and 48 during the Maintenance Phase.
| mmHg | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| Diastolic Blood Pressure at Week 16 (N=1, 6, 9) | 10.0 ± NA | 6.6 ± 11.3 | 4.9 ± 13.3 |
| Diastolic Blood Pressure at Week 48 (N=1, 4, 4) | 2.0 ± NA | 7.0 ± 11.3 | 8.5 ± 8.2 |
| Systolic Blood Pressure at Week 16 (N=1, 6, 9) | 22.0 ± NA | 2.7 ± 12.2 | 9.7 ± 14.1 |
| Systolic Blood Pressure at Week 48 (N=1, 4, 4) | 5.0 ± NA | 1.0 ± 17.1 | 12.0 ± 8.6 |
Pulse rate was obtained while the participant was sitting down and measured in beats per minute (bpm). During the induction phase pulse rate was collected 30 minutes prior to dosing and every 30 minutes for the duration of the ipilimumab infusion. Pulse rate was recorded at Weeks 1, 4, 7, 10, 13, 16, 19, and 22 during the Induction Phase, and at Weeks 24, 36, and 48 during the Maintenance Phase.
| bpm | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| Pulse Rate at Week 16 (N=1, 6, 9) | 24.0 ± NA | 0.3 ± 13.9 | -0.7 ± 15.9 |
| Pulse Rate at Week 48 (N=1, 4, 4) | -3.0 ± NA | -9.5 ± 13.6 | 7.5 ± 10.3 |
Respiration rate was obtained while the participant was sitting down and measured in breaths per minute (bpm). During the induction phase respiration rate was collected 30 minutes prior to dosing and every 30 minutes for the duration of the ipilimumab infusion. Respiration rate was recorded at Weeks 1, 4, 7, 10, 13, 16, 19, and 22 during the Induction Phase, and at Weeks 24, 36, and 48 during the Maintenance Phase.
| bpm | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| Respiration Rate at Week 16 (N=1, 5, 6) | 0 ± NA | 1.4 ± 2.4 | -0.8 ± 2.2 |
| Respiration Rate at Week 48 (N=1, 3, 3) | -2.0 ± NA | -2.7 ± 1.2 | -1.3 ± 1.2 |
Temperature was obtained while the participant was sitting down and was measured in degrees Fahrenheit (F). During the induction phase this vital sign was collected 30 minutes prior to dosing and every 30 minutes for the duration of the ipilimumab infusion. Temperature was recorded at Weeks 1, 4, 7, 10, 13, 16, 19, and 22 during the Induction Phase, and at Weeks 24, 36, and 48 during the Maintenance Phase.
| degrees F | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| Temperature at Week 16 (N=1, 6, 9) | -0.5 ± NA | -0.1 ± 0.8 | 0.2 ± 0.9 |
| Temperature at Week 48 (N=1, 4, 4) | 0.4 ± NA | 0.0 ± 0.7 | -0.2 ± 0.7 |
Hemoglobin was measured in grams per deciliter (g/dL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 10.0 - less than (\<) lower limit of normal (LLN); GRADE (2): 8.0 - \< 10.0; GRADE (3): 6.5 - \< 8.0; GRADE (4): \< 6.5
| participants | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| Hemoglobin Grade 0 | 3 | 4 | 5 |
| Hemoglobin Grade 1 | 9 | 13 | 10 |
| Hemoglobin Grade 2 | 8 | 1 | 4 |
| Hemoglobin Grade 3 | 0 | 1 | 0 |
| Hemoglobin Not Reported | 0 | 0 | 1 |
Leukocytes are measured as \*10\^3 cells per microliter (c/µL). National Cancer Institute Common Terminology Criteria (CTC) version (v) 3.0 was used to determine Grade. GRADE (1): 3.0 - \< LLN; GRADE (2): 2.0 - \< 3.0; GRADE (3): 1.0 - \< 2.0; GRADE (4): \< 1.0.
| participants | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| Leukocytes Grade 0 | 8 | 13 | 17 |
| Leukocytes Grade 1 | 4 | 4 | 1 |
| Leukocytes Grade 2 | 2 | 2 | 1 |
| Leukocytes Grade 3 | 5 | 0 | 0 |
| Leukocytes Grade 4 | 1 | 0 | 0 |
| Leukocytes Not Reported | 0 | 0 | 1 |
Lymphocytes (absolute) were measured as \*10\^3 cells per microliter (c/µL). National Cancer Institute Common Terminology Criteria (CTC) version (v) 3.0 was used to determine Grade. GRADE (1): 0.8 - \< 1.5; GRADE (2): 0.5 - \< 0.8; GRADE (3): 0.2 - \< 0.5; GRADE (4): \< 0.2
| participants | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| Lymphocytes Grade 0 | 4 | 5 | 6 |
| Lymphocytes Grade 1 | 12 | 13 | 11 |
| Lymphocytes Grade 2 | 3 | 1 | 3 |
| Lymphocytes Grade 3 | 1 | 0 | 0 |
Neutrophils (absolute) are measured as \*10\^3 cells per microliter (c/µL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 1.5 - \< 2.0; GRADE (2): 1.0 - \< 1.5; GRADE (3): 0.5 - \< 1.0; GRADE (4): \< 0.5
| participants | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| Neutrophils Grade 0 | 20 | 18 | 19 |
| Neutrophils Grade 1 | 0 | 0 | 1 |
| Neutrophils Grade 3 | 0 | 1 | 0 |
Neutrophils plus bands (absolute) were measured as \*10\^3 cells per microliter (c/µL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 1.5 - \< 2.0; GRADE (2): 1.0 - \< 1.5; GRADE (3): 0.5 - \< 1.0; GRADE (4): \< 0.5.
| participants | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| Neutrophils Plus Bands Grade 0 | 20 | 18 | 19 |
| Neutrophils Plus Bands Grade 1 | 0 | 0 | 1 |
| Neutrophils Plus Bands Grade 3 | 0 | 1 | 0 |
Platelets were measured as \*10\^9 cells per liter (c/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 75.0 - \< LLN; GRADE (2): 50.0 - \< 75.0; GRADE (3): 25.0 - \< 50.0; GRADE (4): \< 25.0.
| participants | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| Platelet Count Grade 0 | 20 | 19 | 18 |
| Platelet Count Grade 1 | 0 | 0 | 2 |
ALT was measured as Units per Liter (U/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 - 2.5 \* upper limits of normal (ULN); GRADE (2): \> 2.5 - 5.0 \* ULN; GRADE (3): \> 5.0 - 20.0 \* ULN; GRADE (4): \> 20.0 \* ULN.
| participants | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| ALT Grade 0 | 18 | 18 | 16 |
| ALT Grade 1 | 2 | 1 | 3 |
| ALT Grade 2 | 0 | 0 | 1 |
AST was measured as Units per Liter (U/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 - 2.5 \* upper limits of normal (ULN); GRADE (2): \> 2.5 - 5.0 \* ULN; GRADE (3): \> 5.0 - 20.0 \* ULN; GRADE (4): \> 20.0 \* ULN.
| participants | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| AST Grade 0 | 18 | 18 | 15 |
| AST Grade 1 | 2 | 1 | 4 |
| AST Grade 2 | 0 | 0 | 1 |
Albumin was measured in grams per deciliter (g/dL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \< LLN - 3.0; GRADE (2): \< 3.0 - 2.0; GRADE (3): \< 2.0 g/dL.
| participants | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| Albumin Grade 0 | 17 | 14 | 14 |
| Albumin Grade 1 | 3 | 5 | 6 |
Alkaline Phosphatase was measured as Units per Liter (U/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 - 2.5 \* upper limits of normal (ULN); GRADE (2): \> 2.5 - 5.0 \* ULN; GRADE (3): \> 5.0 - 20.0 \* ULN; GRADE (4): \> 20.0 \* ULN.
| participants | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| Alkaline Phosphatase Grade 0 | 14 | 18 | 18 |
| Alkaline Phosphatase Grade 1 | 6 | 1 | 0 |
| Alkaline Phosphatase Grade 2 | 0 | 0 | 2 |
Total Bilirubin was measured as milligrams per deciliter (mg/dL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 - 1.5 \* upper limits of normal (ULN); GRADE (2): \> 1.5 - 3.0 \* ULN; GRADE (3): \> 3.0 - 10.0 \* ULN; GRADE (4): \> 10.0 \* ULN.
| participants | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| Total Bilirubin Grade 0 | 20 | 17 | 18 |
| Total Bilirubin Grade 1 | 0 | 1 | 2 |
| Total Bilirubin Grade 2 | 0 | 1 | 0 |
Serum potassium was measured as milliequivalents per liter (mEq/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 3.0 - \< LLN OR \> ULN - 5.5;; GRADE (2): \> 5.5 - 6.0; GRADE (3): 2.5 - \< 3.0 \> 6.0 - 7.0; GRADE (4): \< 2.5 mEq/L.
| participants | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| Serum Potassium (High) Grade 0 | 20 | 17 | 17 |
| Serum Potassium (High) Grade 1 | 0 | 2 | 1 |
| Serum Potassium (High) Grade 2 | 0 | 0 | 2 |
Amylase was measured as units per liter (U/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 - 1.5 \* upper limits of normal (ULN); GRADE (2): \> 1.5 - 2.0 \* ULN; GRADE (3): \> 2.0 - 5.0 \* ULN; GRADE (4): \> 5.0 \* ULN.
| participants | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| Total Amylase Grade 0 | 20 | 19 | 16 |
| Total Amylase Grade 1 | 0 | 0 | 2 |
| Total Amylase Grade 2 | 0 | 0 | 1 |
| Total Amylase Grade 3 | 0 | 0 | 1 |
Total Calcium was measured as milligrams per deciliter (mg/dL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 8.0 - \< LLN OR \> ULN - 11.5; GRADE (2): 7.0 - \< 8.0 \> 11.5 - 12.5; GRADE (3): 6.0 - \< 7.0 \> 12.5 - 13.5; GRADE (4): \< 6.0 \> 13.5 mg/dL.
| participants | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| Total Calcium (High) Grade 0 | 18 | 19 | 19 |
| Total Calcium (High) Grade 1 | 2 | 0 | 1 |
Total Lipase (as measured with a turbidimetric assay) was measured as units per liter (U/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 - 1.5 \* ULN; GRADE (2): \> 1.5 - 2.0 \* ULN; GRADE (3): \> 2.0 - 5.0 \* ULN; GRADE (4): \> 5.0 X ULN.
| participants | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| Total Lipase Grade 0 | 12 | 6 | 4 |
| Total Lipase Grade 1 | 1 | 0 | 0 |
| Total Lipase Grade 4 | 0 | 0 | 1 |
| Total Lipase Not Reported | 7 | 13 | 15 |
Uric acid was measured as milligrams per deciliter (mg/dL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \> 1.0 \* ULN - 10.0; GRADE (4): \> 10.0 mg/dL.
| participants | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| Uric Acid Grade 0 | 20 | 19 | 17 |
| Uric Acid Grade 1 | 0 | 1 | 3 |
Collected over Day 1 up to last patient last visit (LPLV) 30 October 2012. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Paclitaxel, Carboplatin, Ipilimumab | — | 12/20 (60%) | 20/20 (100%) |
| Dacarbazine, Ipilimumab | — | 10/19 (52.6%) | 19/19 (100%) |
| Ipilimumab | — | 14/20 (70%) | 20/20 (100%) |
| Event | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 8/20 | 1/19 | 2/20 |
| Abdominal painGastrointestinal disorders | 0/20 | 4/19 | 1/20 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/20 | 1/19 | 0/20 |
| DiarrhoeaGastrointestinal disorders | 1/20 | 1/19 | 3/20 |
| PyrexiaGeneral disorders | 3/20 | 1/19 | 1/20 |
| HypotensionVascular disorders | 0/20 | 2/19 | 1/20 |
| Autoimmune hepatitisHepatobiliary disorders | 1/20 | 2/19 | 0/20 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 2/20 | 0/19 | 0/20 |
| FatigueGeneral disorders | 2/20 | 0/19 | 0/20 |
| Mental status changesPsychiatric disorders | 0/20 | 0/19 | 2/20 |
| Event | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab |
|---|---|---|---|
| FatigueGeneral disorders | 12/20 | 18/19 | 12/20 |
| RashSkin and subcutaneous tissue disorders | 16/20 | 11/19 | 17/20 |
| NauseaGastrointestinal disorders | 12/20 | 15/19 | 7/20 |
| PruritusSkin and subcutaneous tissue disorders | 13/20 | 14/19 | 15/20 |
| DiarrhoeaGastrointestinal disorders | 10/20 | 12/19 | 12/20 |
| AlopeciaSkin and subcutaneous tissue disorders | 12/20 | 1/19 | 3/20 |
| HyperglycaemiaMetabolism and nutrition disorders | 12/20 | 6/19 | 5/20 |
| Haemoglobin decreasedInvestigations | 11/20 | 7/19 | 4/20 |
| Aspartate aminotransferase increasedInvestigations | 5/20 | 10/19 | 3/20 |
| HeadacheNervous system disorders | 7/20 | 10/19 | 6/20 |
All randomized and treated participants
| Age, Categorical(Participants) | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 15 | 12 | 12 | 39 |
| >=65 years | 5 | 7 | 8 | 20 |
| Age, Continuous(years) | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab | Total |
|---|---|---|---|---|
| Mean | 55 ± 14 | 54 ± 17 | 60 ± 11 | 57 ± 14 |
| Sex: Female, Male(Participants) | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab | Total |
|---|---|---|---|---|
| Female | 7 | 6 | 8 | 21 |
| Male | 13 | 13 | 12 | 38 |
| Region of Enrollment(participants) | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab | Total |
|---|---|---|---|---|
| United States | 20 | 19 | 20 | 59 |
| Eastern Cooperative Oncology Group (ECOG)(participants) | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab | Total |
|---|---|---|---|---|
| 0 | 14 | 17 | 16 | 47 |
| 1 | 6 | 1 | 4 | 11 |
| 2 | 0 | 0 | 0 | 0 |
| Not Reported | 0 | 1 | 0 | 1 |
| Number of Target Lesions(Participants) | Paclitaxel, Carboplatin, Ipilimumab | Dacarbazine, Ipilimumab | Ipilimumab | Total |
|---|---|---|---|---|
| 1 lesion | 4 | 3 | 4 | 11 |
| 2 lesions | 3 | 3 | 0 | 6 |
| 3 lesions | 3 | 4 | 4 | 11 |
| 4 lesions | 0 | 2 | 5 | 7 |
| >=5 lesions | 10 | 7 | 7 | 24 |
The record gives a start of Feb 2009, a primary completion of Nov 2009 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2014, 4 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ipilimumab · Carboplatin · Paclitaxel · Dacarbazine